Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Mar 28;92(6):1038-45.
doi: 10.1038/sj.bjc.6602477.

A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

E Senkus-Konefka  1 , R Dziadziuszko, E Bednaruk-Młyński, A Pliszka, J Kubrak, A Lewandowska, K Małachowski, M Wierzchowski, M Matecka-Nowak, J Jassem
Affiliations
Clinical Trial

A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC)

E Senkus-Konefka et al. Br J Cancer. .

Abstract

A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5 fractions (fr)/5 days (arm A) or 16 Gy/2 fr/day 1 and 8 (arm B). There were 90 men and 10 women aged 47-81 years (mean 66), performance status 1-4 (median 2). The major clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects were assessed using patient's chart, doctor's scoring of symptomatic change and chest X-ray. Study end points included degree and duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination. Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patients' self-assessment of cough, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 2
Figure 2
Patients' self-assessment of dyspnoea, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 3
Figure 3
Patients' self-assessment of haemoptysis, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 4
Figure 4
Patients' self-assessment of chest pain, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 5
Figure 5
Patients' self-assessment of dysphagia, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 6
Figure 6
Patients' self-assessment of superior vena cava syndrome, according to treatment arm and week of follow-up. Boxplots represent mean ±95% confidence interval; N=number of patients.
Figure 7
Figure 7
Survival according to treatment group (n=100).
See this image and copyright information in PMC

References

    1. Abratt RP, Shepherd LJ, Salton DG (1995) Palliative radiation for stage 3 non-small cell lung cancer – a prospective study of two moderately high dose regimens. Lung Cancer 13: 137–143 - PubMed
    1. American Society of Clinical Oncology (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15: 2996–3018 - PubMed
    1. Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater JL (2002) Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 54: 719–728 - PubMed
    1. Cross CK, Berman S, Buswell L, Johnson B, Baldini EH (2004) Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58: 1098–1105 - PubMed
    1. Drozd-Lula M, Jassem J, Karnicka-Mlodkowska H.. Effect of radiotherapy on quality of survival in locally advanced non-small cell lung cancer. Abstracts of the 4th Central European Lung Cancer Conference, A156. 1996